# Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

> **NCT04375384** · PHASE2 · RECRUITING · sponsor: **Wake Forest University Health Sciences** · enrollment: 38 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Metastatic Head-and-neck Squamous-cell Carcinoma

## Interventions

- **DRUG:** Cetuximab
- **OTHER:** Questionnaire administration
- **OTHER:** Quality of life assessment

## Key facts

- **NCT ID:** NCT04375384
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04375384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04375384, "Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04375384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*